| Assessment Status | Rapid Review Complete |
| HTA ID | 22057 |
| Drug | Lenvatinib |
| Brand | Kisplyx® |
| Indication | For the treatment of adults with advanced renal cell carcinoma, in combination with pembrolizumab, as first-line treatment |
| Assessment Process | |
| Rapid review commissioned | 15/08/2022 |
| Rapid review completed | 22/09/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lenvatinib in combination with pembrolizumab for first-line treatment of patients with advanced RCC compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
